Novel technologies for high multiplex detection

In the last 15 years, we have developed a wide panel of in vitro and in silico technologies for the characterisation of pathogens (species, antibiotic resistance, and virulence factor identification).

In our unit, assays detecting up to 1000 different genetic targets with a single test were designed including their experimental evaluation and pre-clinical validation. Based on this comprehensive know-how, we can offer our partners and customers a wide range of services such as technology consulting, assay development, and support for the clinical validation of the final assays.

  • Microbial diagnostics
  • Infection prevention
  • Antimicrobial stewardship
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Research
  • Development
  • Validation
  • Market entry
  • Marketed product

  • Institute
  • Company
  • Academia
  • NGO
  • Government

  • License
  • Co-develop
  • Outsource
  • Sell
  • Joint Venture

Funding organisation:
  • OTHER / NA
  • CARB-X
  • FIND

Infectious disease area:
  • UTI
  • STI
  • BSI
  • RTI
  • GII
  • SSTI
  • CNSI
  • IAI
  • SSI

Geographic origin:
  • Eurasia
  • North America
  • South America
  • Africa
  • Oceania

Public research organisation

• Automated sequence database management
• High-throughput design tools for DNA-based multiplex assays
• Design of complex protein/DNA nanostructures

Experimental evaluation of primer artefacts
• Nano-fluidic qPCR for identification of unintended background DNA and primer interactions
• NGS-based primer dimer sequencing
• In silico analysis of oligonucleotide interactions

Assay performance analysis

Assay development

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed